Five things for pharma marketers to know: Friday, September 23, 2016

Five things for pharma marketers to know: Friday, September 23, 2016

Anthem and Cigna accuse each other of violating merger terms; Alzheimer's experimental drug fails late-stage study; study calls for new approach to eradicate global epidemics

Five things for pharma marketers to know: Thursday, September 22, 2016

Five things for pharma marketers to know: Thursday, September 22, 2016

Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus

Five things for pharma marketers to know: Wednesday, September 21, 2016

Five things for pharma marketers to know: Wednesday, September 21, 2016

Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight

Campaign seeks to educate doctors about when to prescribe opioids

Campaign seeks to educate doctors about when to prescribe opioids

Some physicians say they believe they have a responsibility to address the opioid epidemic, but misinformation may hinder them in that pursuit.

WebMD CEO departs, replaced by president

WebMD CEO departs, replaced by president

WebMD said David Schlanger left the company under mutual agreement, and that Steven Zatz replaced him as CEO.

Ascension begins hospital-rebranding push

Ascension begins hospital-rebranding push

Ascension worked with several Omnicom agencies on the rebranding push, including FleishmanHillard and Siegel & Gale.

Five things for pharma marketers to know: Tuesday, September 20, 2016

Five things for pharma marketers to know: Tuesday, September 20, 2016

GSK names new CEO; the FDA approves first Duchenne muscular dystrophy drug; Sanofi files Lantus patent lawsuit against Merck

Alexion uses superheroes, social media to raise rare-disease awareness

Alexion uses superheroes, social media to raise rare-disease awareness

Alexion launched a new superhero-themed awareness campaign to draw attention to four rare diseases that its products treat.

Five things for pharma marketers to know: Monday, September 19, 2016

Five things for pharma marketers to know: Monday, September 19, 2016

Some U.S. hospitals still haven't received Valeant discounts; U.N. General Assembly will discuss antibiotic resistance; AstraZeneca diabetes drugs lowered blood sugar in study

Q&A: Cardiogram's Ballinger on using the Apple Watch to track heart rate

Q&A: Cardiogram's Ballinger on using the Apple Watch to track heart rate

The app's co-founder discusses how it's educating patients and physicians about artificial intelligence and why Cardiogram is different from other heart-rate tracking apps.

The FDA warns drugmakers over promotion of experimental opioid

The FDA warns drugmakers over promotion of experimental opioid

The OPDP sent its second untitled letter this week, this time to Durect and Pain Therapeutics over the presentation of Remoxy ER.

Five things for pharma marketers to know: Friday, September 16, 2016

Five things for pharma marketers to know: Friday, September 16, 2016

The FDA approves a combination of aspirin and heartburn medication; Teva partners with Intel to develop wearable; New Mexico AG sues BMS and Sanofi

Five things for pharma marketers to know: Thursday, September 15, 2016

Five things for pharma marketers to know: Thursday, September 15, 2016

Mylan CEO to appear before House committee about EpiPen pricing; job-related health premiums rise; GSK's experimental shingles vaccine shows 90% effectiveness

Pharma's access to docs declines as nonpersonal promotion increases

Pharma's access to docs declines as nonpersonal promotion increases

Sales reps are now more likely to engage with physicians through nonpersonal promotion than in-person visits with doctors at their offices, a ZS report finds.

Five things for pharma marketers to know: Wednesday, September 14, 2016

Five things for pharma marketers to know: Wednesday, September 14, 2016

Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan's executive pay is now under scrutiny

Government watchdog finds that most but not all generic drug prices are falling

Government watchdog finds that most but not all generic drug prices are falling

A new government investigation found that most but not all prices for generic drugs dispensed by Medicare Part D fell from 2010 to 2015.

On Facebook, 97% of brands still rely on organic reach, says BBDO study

On Facebook, 97% of brands still rely on organic reach, says BBDO study

For years the social network has been telling advertisers they must pay to magnify their exposure, but most continue to resist.

Five things for pharma marketers to know: Tuesday, September 13, 2016

Five things for pharma marketers to know: Tuesday, September 13, 2016

Drugmakers routinely pay ghostwriters to write industry-funded research articles; Horizon to buy Raptor for $800 million; WellDoc partners with J&J

The FDA criticizes Pfizer's safety study for Chantix

The FDA criticizes Pfizer's safety study for Chantix

The regulator cited inconsistencies with how safety trial data was recorded in a report released ahead of the advisory committee's meeting on Wednesday.

Five things for pharma marketers to know: Monday, September 12, 2016

Five things for pharma marketers to know: Monday, September 12, 2016

Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google's Verily partner in diabetes

WebMD's Leming on audience development and lessons from CNN.com

WebMD's Leming on audience development and lessons from CNN.com

The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?

One analyst envisions how a first-line approval could set up Keytruda for success in other settings.

Five things for pharma marketers to know: Friday, September 9, 2016

Five things for pharma marketers to know: Friday, September 9, 2016

New Cigna campaign features TV doctors; Walgreens to divest 1,000 stores; senators question Aetna's health exchange exit

What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

Five things for pharma marketers to know: Thursday, September 8, 2016

Five things for pharma marketers to know: Thursday, September 8, 2016

A new study found that orphan drug spending will slow through 2018; senators open inquiry into Mylan; Shires launches branded campaign

Sex, chocolate, and disability: What marketers can learn from Mars' Maltesers campaign

Sex, chocolate, and disability: What marketers can learn from Mars' Maltesers campaign

The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.

The FDA sends untitled letter to Jazz subsidiary over ASCO display

The FDA sends untitled letter to Jazz subsidiary over ASCO display

The regulator charged Celator Pharmaceuticals with promoting an experimental drug as safe and effective even though it has not been approved.

Merkle taps Mike Goldin as SVP of health

Merkle taps Mike Goldin as SVP of health

The new SVP and GM of health believes that the Dentsu Aegis deal would provide scale and efficiencies.

Five things for pharma marketers to know: Wednesday, September 7, 2016

Five things for pharma marketers to know: Wednesday, September 7, 2016

BIO launches ad campaign defending drugmakers; GSK's experimental COPD drug reduces flare-ups in patients; NY attorney general to investigate Mylan

CEO: Allergan will limit price increases for branded drugs

CEO: Allergan will limit price increases for branded drugs

CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.

W2O acquires Pure Communications, plans to create new health and tech agency

W2O acquires Pure Communications, plans to create new health and tech agency

Pure Communications CEO Andrea Johnston will lead the combined agency.

Five things for pharma marketers to know: Tuesday, September 6, 2016

Five things for pharma marketers to know: Tuesday, September 6, 2016

MannKind plans to develop inhalable epinephrine; lawmakers accuse Mylan of evading paying higher Medicaid rebates; NICE rejects Roche's cancer drug

Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Novartis sets out to debunk misconception that only smokers get lung cancer

Novartis sets out to debunk misconception that only smokers get lung cancer

Approximately 10% to 15% of lung cancer patients have never smoked and have developed the disease due to genetic alterations.

Five things for pharma marketers to know: Friday, September 2, 2016

Five things for pharma marketers to know: Friday, September 2, 2016

Hillary Clinton releases drug-pricing plan; patent for Teva's Copaxone is invalidated; Roche's immunotherapy extends life

MM&M's top 5 stories in August 2016

MM&M's top 5 stories in August 2016

Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck's Keytruda takes the lead in first-line cancer

The FDA asks for input on off-label comms

The FDA asks for input on off-label comms

The FDA will hold a public hearing in November to gather input on how it should regulate certain off-label communications.

Report: 3 tips for pharma to provide beyond-the-pill services

Report: 3 tips for pharma to provide beyond-the-pill services

Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.

Five things for pharma marketers to know: Thursday, September 1, 2016

Five things for pharma marketers to know: Thursday, September 1, 2016

Novartis to fold its cell and gene therapy business; Novo Nordisk CEO to retire; the FDA issues a safety warning for opioids taken with anti-anxiety drugs

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

Mylan's branded ad spending on the EpiPen rose 357% — to $43 million in 2015 — over five years

In 2011 the drugmaker spent $9.4 million on branded ads for the EpiPen. By 2015, branded ad spending hit $43 million.

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Data, Technology, and Medicine: How They Intersect

Data, Technology, and Medicine: How They Intersect

The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.

Five things for pharma marketers to know: Tuesday, August 30, 2016

Five things for pharma marketers to know: Tuesday, August 30, 2016

Walgreens Boots partners with PBM; Clinton proposes mental health plan; BI and Qualcomm to develop connected inhaler

Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

Health exchanges, Obama administration challenged by recent insurer exits

Health exchanges, Obama administration challenged by recent insurer exits

The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.

Five things for pharma marketers to know: Monday, August 29, 2016

Five things for pharma marketers to know: Monday, August 29, 2016

Mylan to launch generic EpiPen; the majority of NCCN guideline writers report conflicts of interest; Sanofi reports new trial data for Praluent

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Five things for pharma marketers to know: Friday, August 26, 2016

Five things for pharma marketers to know: Friday, August 26, 2016

Sarah Jessica Parker cuts ties with Mylan over pricing controversy; lung-cancer physicians turn to Keytruda; Merck KGaA diversifies its business

Five things for pharma marketers to know: Thursday, August 25, 2016

Five things for pharma marketers to know: Thursday, August 25, 2016

Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated

Shire taps Jennifer Aniston for awareness campaign as it enters the eye care market

Shire taps Jennifer Aniston for awareness campaign as it enters the eye care market

The drugmaker expects the multi-channel initiative to lay its foundation in the ophthalmology market.

Anti-smoking group Truth releases musical FOMO spot for MTV Video Music Awards

Anti-smoking group Truth releases musical FOMO spot for MTV Video Music Awards

The anti-tobacco movement Truth is hitting young people in their pocketbooks with a new spot called "Squadless."

Five things for pharma marketers to know: Wednesday, August 24, 2016

Five things for pharma marketers to know: Wednesday, August 24, 2016

Retzlaff files a complaint against Turing; Pfizer to buy antibiotics from AstraZeneca; Mylan's marketing for EpiPen faces criticism

Five things for pharma marketers to know: Tuesday, August 23, 2016

Five things for pharma marketers to know: Tuesday, August 23, 2016

Grassley blasts Mylan over EpiPen price increases; Portola Pharmaceuticals receives CRL letter for reversal agent; the FDA approves Pfizer's opioid

In Medivation deal, Pfizer will gain an oncology blockbuster

In Medivation deal, Pfizer will gain an oncology blockbuster

Pfizer's commercial expertise in urology and oncology could help propel Medivation's Xtandi to new heights.

Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Long neglected, the osteoporosis market prepares for new entrants

Long neglected, the osteoporosis market prepares for new entrants

The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.

Five things for pharma marketers to know: Monday, August 22, 2016

Five things for pharma marketers to know: Monday, August 22, 2016

Pfizer to acquire cancer drugmaker Medivation; Valeant names new CFO; Apple acquires health data startup

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

Reimbursement rather than Brexit more likely to impact how drugmakers order global launches

The current reimbursement climate is more likely to impact how drugmakers order their global product launches than the U.K.'s vote to exit the E.U.

Five things for pharma marketers to know: Friday, August 19, 2016

Five things for pharma marketers to know: Friday, August 19, 2016

Another study finds doctors who receive gifts from drugmakers prescribe their drugs; Part D spending rose 17% in 2014; Mallinckrodt to open New Jersey site

Expect healthcare agencies to make more digital acquisitions: report

Expect healthcare agencies to make more digital acquisitions: report

Mergers and acquisitions targeting digital and data capabilities increased 60% to $1 billion in the first half of 2016.

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

Read the complete August 2016 digital edition

Read the complete August 2016 digital edition

Read about MM&M's inaugural Hall of Femme event and the rest of the MM&M August issue.

Five things for pharma marketers to know: Wednesday, August 17, 2016

Five things for pharma marketers to know: Wednesday, August 17, 2016

AHIP study says half of orphan-drug usage is for non-orphan indications; Studies of GSK weight-loss pill underestimated side effects; ViiV starts HIV trial

Healthline's traffic rises, putting it closer to WebMD and Everyday Health

Healthline's traffic rises, putting it closer to WebMD and Everyday Health

The health site had a 44% increase in unique visitors in July 2016, compared to the same month a year ago.

Cleveland Clinic aims to get guys talking in first men's health campaign

Cleveland Clinic aims to get guys talking in first men's health campaign

The Cleveland Clinic has launched its first national men's health campaign, MENtion It, to encourage men to be more proactive about their health.

Drugmakers condemn ICER-funded study on PCSK9s

Drugmakers condemn ICER-funded study on PCSK9s

A new study published in JAMA said PCSK9 inhibitors are not worth their high prices.

Five things for pharma marketers to know: Tuesday, August 16, 2016

Five things for pharma marketers to know: Tuesday, August 16, 2016

OncoGenex's prostate cancer drug fails in clinical trial; Aetna to exit exchanges in 11 states; pregnant women taking acetaminophen have higher risks for their children

Lobbyists create off-label principles following FDA lawsuits

Lobbyists create off-label principles following FDA lawsuits

PhRMA and BIO, which represent life sciences firms, developed principles about sharing truthful and non-misleading information with payers and providers.

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

One year on: Inside Bayer's effort to get prostate cancer patients to speak up

Bayer recently tapped Ken Griffey Sr. and Ken Griffey Jr. — the first father-son duo to be inducted into the Baseball Hall of Fame — as spokespeople.

Healthcare agencies not immune to gender bias, parity issues

Healthcare agencies not immune to gender bias, parity issues

Agencies are testing out strategies to reach gender parity at a time when questions of discrimination are still front and center.

Five things for pharma marketers to know: Monday, August 15, 2016

Five things for pharma marketers to know: Monday, August 15, 2016

Express Scripts does not disclose names of formulary board members; Endo withdrew abuse-deterrent formulation for opioid; BI to collect real-world data on Praxbind

DTC ads for Opdivo face further backlash

DTC ads for Opdivo face further backlash

Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.

Johnson & Johnson's Alison Lewis on building memorable brands

Johnson & Johnson's Alison Lewis on building memorable brands

The company's first global consumer CMO shares the challenges of delivering global campaigns and meeting local market needs.

Five things for pharma marketers to know: Friday, August 12, 2016

Five things for pharma marketers to know: Friday, August 12, 2016

Study finds estimated drug costs are often overstated; physician criticizes DTC ad for Opdivo; Merck HPV ads are criticized for being manipulative

Five things for pharma marketers to know: Thursday, August 11, 2016

Five things for pharma marketers to know: Thursday, August 11, 2016

Valeant is under federal investigation; Lilly's breast-cancer drug fails to meet efficacy criteria; new policy opens up medical research of marijuana

Analysts: Payers moving to address MS market as prices rise

Analysts: Payers moving to address MS market as prices rise

The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.

W2O faces gender discrimination suit from former staffer

W2O faces gender discrimination suit from former staffer

Lynn Fox is suing W2O. She was laid off in March, seven months after the agency network bought her San Francisco-based boutique, Fox Communications.

Five things for pharma marketers to know: Wednesday, August 10, 2016

Five things for pharma marketers to know: Wednesday, August 10, 2016

A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad "misleading;" Valeant to sell non-core assets worth $8 billion

Valeant salesforce stabilizes as Xifaxan rebounds

Valeant salesforce stabilizes as Xifaxan rebounds

Valeant had deployed roughly 100 additional sales reps this year to promote Xifaxan's indication in hepatic encephalopathy.

Verywell and Cleveland Clinic to partner on health content site

Verywell and Cleveland Clinic to partner on health content site

The companies said they are also exploring opportunities to allow Cleveland Clinic experts to contribute to Verywell in the future.

Five things for pharma marketers to know: Tuesday, August 9, 2016

Five things for pharma marketers to know: Tuesday, August 9, 2016

Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial

Opdivo bet backfires, creates opening for Merck to pursue DTC

Opdivo bet backfires, creates opening for Merck to pursue DTC

A massive disappointment for Bristol-Myers Squibb's Opdivo in first-line lung cancer has leveled the playfield for Merck's Keytruda.

Five things for pharma marketers to know: Monday, August 8, 2016

Five things for pharma marketers to know: Monday, August 8, 2016

Valeant reorganizes executive team; experimental asthma drug developed by Novartis shows promising results; Teva launches generic Gleevec

Event company acquires AstraZeneca's medical meetings app

Event company acquires AstraZeneca's medical meetings app

The event technology platform plans to integrate a conference note-taking app developed by AstraZeneca and DigitasLBi.

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Five things for pharma marketers to know: Friday, August 5, 2016

Five things for pharma marketers to know: Friday, August 5, 2016

Opdivo fails to meet endpoint in new lung cancer patients; abuse-deterrent drug gets nod from FDA panel; Cephalon settles pay-for-delay case

Cigna's first global brand campaign targets expats

Cigna's first global brand campaign targets expats

The campaign will run in an integrated digital marketing format using channels such as Facebook, Twitter, and Youtube.

Five things for pharma marketers to know: Thursday, August 4, 2016

Five things for pharma marketers to know: Thursday, August 4, 2016

Researchers test Zika vaccine; Aetna contacts doctors who prescribe high rates of opioids; half of pediatric trials are never published or completed

Fitbit hires Walgreens exec as digital health VP

Fitbit hires Walgreens exec as digital health VP

The popular fitness tracker maker hired Adam Pellegrini, Walgreens' VP of digital health, to boost pharma and healthcare deals.

PBMs unveil 2017 formularies, retain focus on exclusions

PBMs unveil 2017 formularies, retain focus on exclusions

Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.

Five things for pharma marketers to know: Wednesday, August 3, 2016

Five things for pharma marketers to know: Wednesday, August 3, 2016

Merck and Allergan reportedly vying to buy Biogen; drugmakers fight California measure capping drug prices; few seniors use the web to look for health info

Philips launches health watch and 3 other connected devices

Philips launches health watch and 3 other connected devices

The company launched a health watch, a connected scale, a blood pressure monitor, and a thermometer.

Kevin Roberts resigns from Saatchi & Saatchi after gender diversity controversy

Kevin Roberts resigns from Saatchi & Saatchi after gender diversity controversy

He resigned as Saatchi & Saatchi's executive chairman following his controversial remarks over gender diversity.

Patient-Centricity: There's Always Room for Improvement

Patient-Centricity: There's Always Room for Improvement

It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.

Five things for pharma marketers to know: Tuesday, August 2, 2016

Five things for pharma marketers to know: Tuesday, August 2, 2016

IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets

OPINION

Email Newsletters